We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Sensitive Urine Assay Detects Prostate Cancer

By LabMedica International staff writers
Posted on 29 Aug 2011
An innovative prostate screening test has been developed that may be more sensitive in detecting prostate cancer than traditional screening methods. More...


The test provides an original way to look at prostate cancer diagnosis utilizing a novel biological assay, which differentiates prostate-specific antigen's (PSA) molecular structures arising from cancer versus noncancerous glands.

Scientists at Case Western Reserve University School of Medicine collaborating with other institutions, studied a urine-based test that works differently than most prostate screening methods. They used a novel assay to separate PSA protein structures as being linked to either a “cancer” or “noncancer” pathologic diagnosis based on ultrasound-guided biopsy. Instead of attempting to find a single genetic biomarker, which predicts the presence of cancer, the Prostate-specific Antigen/Solvent Interaction Analysis (PSA/SIA) assay is based on the assumption that there may be myriad different ultrastructural changes in the PSA protein, which define the cancer phenotype.

The PSA/SIA assay determined the relative partitioning of heterogeneous PSA isoform populations in urine between two aqueous phases. The initial study, collected at three clinical sites, followed 222 men, and found that the new screening method had 100% sensitivity with no false negative results and 80.3% specificity showing low false positive results. The accuracy of traditional serum PSA is limited by both relatively high false positive and false negative rates. Current diagnostic strategies that use total PSA to determine the need for biopsy demonstrate false positive rates of approximately 55% to 75%.

The PSA/SIA assay, a product of AnalizaDx (Cleveland, OH, USA) provides ratiometric information independently of PSA concentration. In the preliminary study, analysis of the overall structurally heterogeneous PSA isoform population using the SIA assay showed promising results to be further evaluated in future studies. Arnon Chait, PhD, CEO of AnalizaDx, said, "This new assay is a complete departure from how the scientific community has looked at biomarkers for cancer. Instead of just measuring levels of proteins, we are exploring changes in structure which are associated with cancer.” The study was published online on July 22, 2011, in the journal Urology.

Related Links:
Case Western Reserve University School of Medicine
AnalizaDx




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.